

In the Claims

Please substitute the following claims 13, 14, 18 and 19 for the claims 13, 14, 18 and 19 now pending in the above-identified application.

Please cancel claims 1-12 and 21-23 without prejudice to the filing of future continuing applications.

Please add new claim 25.

CLAIMS

Claims 1 - 12 (Cancelled)

13. (Currently Amended) A prodrug of the compound according to claim ~~1~~ 25 or a salt thereof.
14. (Currently Amended) A pharmaceutical composition comprising the compound according to claim ~~1~~ 25 or a salt thereof and a pharmaceutically acceptable carrier, excipient or diluent.
15. (Original) The pharmaceutical composition according to claim 14, which is a lipid-rich regressing agent or an ACAT inhibitor.
16. (Original) The pharmaceutical composition according to claim 14, which is a prophylactic or therapeutic agent against acute coronary syndrome, acute myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or an agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion.

17. (Original) The agent for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion according to claim 16, which is combined with a HMG-CoA reductase inhibitor.
18. (Currently Amended) A method for regressing a lipid-rich plaque or inhibiting ACAT in a mammal, which comprises administering an effective amount of the compound according to claim ~~1~~ 25 or a salt thereof to the mammal.
19. (Currently Amended) A method for ~~preventing or~~ treating acute coronary syndrome, acute myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion in a mammal, which comprises administering an effective amount of the compound according to claim ~~1~~ 25 or a salt thereof to the mammal.
20. (Previously Presented) The method for regressing, inhibiting progression of or stabilizing an arteriosclerotic lesion according to claim 19, which comprises administering the compound or a salt thereof in combination with a HMG-CoA reductase inhibitor.

Claims 21-23 (Cancelled)

24. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 13 or a salt thereof and a pharmaceutically acceptable carrier, excipient or diluent.

25. (New) (2E)-3-[5-[7-chloro-3-[2-[[2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-chromen-4-yl]phenyl]acrylic acid or a salt thereof.